LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Search

IQVIA Holdings Inc

Închisă

SectorSănătate

166.46 -0.63

Rezumat

Modificarea prețului

24h

Curent

Minim

165.44

Maxim

168.19

Indicatori cheie

By Trading Economics

Venit

1B

1.4B

Vânzări

264M

4.4B

P/E

Medie Sector

23.934

121.746

Marjă de profit

31.187

Angajați

93,000

EBITDA

266M

1B

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+41.78% upside

Dividende

By Dow Jones

Următoarele câștiguri

5 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-6.6B

33B

Deschiderea anterioară

167.09

Închiderea anterioară

166.46

Sentimentul știrilor

By Acuity

40%

60%

87 / 351 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Bullish Evidence

IQVIA Holdings Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

15 feb. 2026, 23:21 UTC

Achiziții, Fuziuni, Preluări

Qube Agrees to Takeover by MAM-Led Consortium Valuing Its Equity at $6.51 Billion

15 feb. 2026, 23:45 UTC

Market Talk

Nikkei May Rise as Fears About AI Disruption Recede -- Market Talk

15 feb. 2026, 23:40 UTC

Market Talk

Gold Falls on Possible Position Adjustments -- Market Talk

15 feb. 2026, 23:06 UTC

Câștiguri

Thai Beverage: Spirits, Beer Businesses Posted Satisfactory EBITDA Growth, Alongside Profit Margin Expansion>Y92.SG

15 feb. 2026, 23:04 UTC

Câștiguri

Thai Beverage 1Q Beer Business EBITDA THB4.64B, Up 4.7% on Year>Y92.SG

15 feb. 2026, 23:04 UTC

Câștiguri

Thai Beverage 1Q Spirits Business EBITDA THB8.50B, Up 6.9% on Year >Y92.SG

15 feb. 2026, 23:01 UTC

Câștiguri

Thai Beverage 1Q EBITDA THB16.75B, Up 1.8% on Year >Y92.SG

15 feb. 2026, 23:01 UTC

Câștiguri

Thai Beverage 1Q FY Sales Revenue THB86.70B, Down 6.0% on Year>Y92.SG

15 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Qube: MAM-Led Offer Implies A$11.7 Billion Enterprise Value

15 feb. 2026, 22:53 UTC

Achiziții, Fuziuni, Preluări

Qube: UniSuper to Transfer 15.07% Stake to Equivalent Ownership of Consortium Holding Structure

15 feb. 2026, 22:52 UTC

Achiziții, Fuziuni, Preluări

Qube Shareholders to Receive A$5.20/Share in Cash

15 feb. 2026, 22:52 UTC

Achiziții, Fuziuni, Preluări

Qube Holdings Agrees to Takeover by Macquarie Asset Management-Led Consortium

15 feb. 2026, 22:22 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO Tania Archibald Speaking on a Call With Media

15 feb. 2026, 22:17 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO: Stresses Whyalla Project Would Have to Make Sense to Shareholders

15 feb. 2026, 22:16 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO: Some Job Cuts Inevitable to Ensure Company is Competitive

15 feb. 2026, 22:14 UTC

Achiziții, Fuziuni, Preluări

BlueScope CEO: Higher Returns Tied to End of Capital Investment Program

15 feb. 2026, 22:14 UTC

Achiziții, Fuziuni, Preluări

BlueScope Steel CEO: Higher Returns After Rebuffed Takeover Bid a 'Natural Coincidence'

15 feb. 2026, 20:48 UTC

Câștiguri

BlueScope: Will Now Target Net Debt of Up to A$1.5 Billion; Will Surpass as Needed

15 feb. 2026, 20:47 UTC

Câștiguri

BlueScope: Expects Full Benefits of Further A$150M Cost Savings in FY 2027

15 feb. 2026, 20:46 UTC

Câștiguri

BlueScope: Recorded Net Annualized Cost Improvements of A$190 Million in 1H

15 feb. 2026, 20:45 UTC

Câștiguri

BlueScope Expects a One-Third Lower 2H Result From Asia Business Vs 1H

15 feb. 2026, 20:44 UTC

Câștiguri

BlueScope Expects 15% Higher 2H Result From North America Business Vs 1H

15 feb. 2026, 20:44 UTC

Câștiguri

BlueScope Expects Lower 2H Result From Australia Business Vs 1H

15 feb. 2026, 20:43 UTC

Câștiguri

BlueScope Expects 2H Underlying Ebit of A$620 Million-A$700 Million

15 feb. 2026, 20:42 UTC

Câștiguri

BlueScope Net Debt A$2.2 Million at Dec. 31

15 feb. 2026, 20:42 UTC

Câștiguri

BlueScope 1H Underlying Ebit A$557.5 Million, Up 81% On-Year

15 feb. 2026, 20:41 UTC

Câștiguri

BlueScope 1H Underlying Ebitda A$915.3 Million, Up 39% On-Year

15 feb. 2026, 20:40 UTC

Câștiguri

BlueScope 1H Underlying Profit A$382.0 Million Vs A$176.4 Million Year Prior

15 feb. 2026, 20:40 UTC

Câștiguri

BlueScope 1H Sales Revenue From Continuing Ops A$8.22 Billion, Up 4% On-Year

15 feb. 2026, 20:39 UTC

Câștiguri

BlueScope Intends to Spend A$310 Million on Buyback, Or Other Returns if Share Repurchases Limited

Comparație

Modificare preț

IQVIA Holdings Inc Așteptări

Obiectiv de preț

By TipRanks

41.78% sus

Prognoză pe 12 luni

Medie 236.69 USD  41.78%

Maxim 266 USD

Minim 200 USD

În baza a 16 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruIQVIA Holdings Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

16 ratings

12

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

150.68 / 153.45Suport & Rezistență

Termen scurt

Bullish Evidence

Termen mediu

Neutral Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

87 / 351 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre IQVIA Holdings Inc

IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a collaboration with argenx SE; and a strategic collaboration with NVIDIA Corporation. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. The company is headquartered in Durham, North Carolina.
help-icon Live chat